Tee Labs Incubatee | LinZight Harnesses AI Privacy Platform & RWD to Help EpimAb Reveal Novel ALPP Target Mechanism in KRAS-Driven Cancers

Key Highlights

  • Clinical Hope Against the “King of Cancers”: Pancreatic cancer is universally recognized as the “King of Cancers,” burdened with exceptionally high mortality rates and severely limited therapeutic options. Consequently, any novel strategy with transformative therapeutic potential marks a critical clinical milestone and commands intense global industry attention.
  • A Paramount Question Answered: While ALPP is an established oncological target, determining the specific cancer types in which it yields the greatest therapeutic efficacy has long been an urgent clinical question. Leveraging real-world data (RWD) from Chinese patient cohorts, LinZight has delivered a precise and definitive answer.
  • Overcoming Drug Resistance Hurdles: Although direct KRAS inhibitors (such as RMC-6236) have achieved encouraging clinical progress, acquired resistance remains a formidable barrier. The dual-targeting strategy combining an ALPP-directed therapy with KRAS inhibition revealed in this study establishes a compelling new scientific rationale to conquer this resistance bottleneck.

LinZight Technology (“LinZight”) and EpimAb Biotherapeutics (“EpimAb”) recently announced a groundbreaking collaborative achievement in therapeutic research targeting pancreatic cancer, widely referred to as the “King of Cancers.”

Pancreatic ductal adenocarcinoma (PAAD) represents one of the malignancies with the poorest clinical prognosis worldwide, with a five-year survival rate of less than 10%. A central hurdle in its clinical management is that over 90% of PAAD patients harbor KRAS gene mutations. While KRAS inhibitors have demonstrated considerable therapeutic promise, drug resistance emerging from monotherapy prevents them from offering curative outcomes. Therefore, identifying novel synergistic targets for rational combination regimens has become imperative to elevate pancreatic cancer clinical efficacy.

Against this backdrop, LinZight harnessed its proprietary, drug-discovery-tailored LinZight AI computing platform—powered by tumor multi-omics and Real-World Data (RWD)—to identify alkaline phosphatase (ALPP/G) as a critical therapeutic target in KRAS-mutant pancreatic cancer (PAAD), providing robust real-world evidence (RWE) to empower EpimAb’s innovative pipeline.

By interrogating longitudinal expression shifts of ALPP/G before and after standard-of-care (SoC) oncology regimens using LinZight AI, the research team discovered a distinct molecular mechanism: ALPP/G expression is substantially upregulated in KRAS-mutant pancreatic cancer. Given that ALPP/G exhibits extremely low or undetectable expression across normal adult human tissues, it emerges as a tumor target with high specificity and a favorable therapeutic window.

This finding provided pivotal R&D validation for EpimAb’s first-in-class ALPP/G × CD3 bispecific T-cell engager (TCE), EM1032. Preclinical in vivo data demonstrated that EM1032 exerted potent tumor growth inhibition in KRAS G12V-mutant pancreatic cancer xenograft models. Crucially, combining EM1032 with the KRAS inhibitor RMC-6236 (daraxonrasib) achieved markedly enhanced tumor control. This empirical synergy closely corroborates the high ALPP/G expression mechanism in KRAS-mutant pancreatic cancer uncovered by LinZight’s real-world data analytics.

Research Background

Due to its dismal prognosis and a median overall survival of merely 6–8 months, pancreatic cancer is notoriously dubbed the “King of Cancers” and remains a leading cause of global cancer-related mortality. In China, the vast majority of patients are diagnosed at advanced or metastatic stages, facing an acute scarcity of curative modalities.

ALPP is an oncofetal antigen aberrantly overexpressed across diverse malignancies. By hydrolyzing extracellular ATP into adenosine, it orchestrates a profoundly immunosuppressive tumor microenvironment (TME), facilitating tumor immune evasion. Furthermore, ALPP triggers downstream pro-oncogenic signaling pathways that fuel cancer cell proliferation. Owing to its dual properties of tumor-specific expression and immunomodulatory activity, ALPP has captured substantial interest from multinational pharmaceutical developers; however, establishing its precise clinical indications and responsive patient populations has historically remained an elusive challenge.

LinZight’s Technical Implementation Pathway

Throughout this collaboration with EpimAb, LinZight leveraged its real-world data AI platform to achieve de novo indication expansion and biomarker discovery tailored to the Chinese oncology patient cohort within an accelerated timeframe of just three months.

Operating under strict adherence to data governance and privacy preservation regulations, the LinZight AI platform seamlessly integrates high-quality, high-completeness multi-omics data from real-world clinical patients—spanning clinicopathological attributes, genomics, and transcriptomics across multiple dimensions—establishing a reliable empirical foundation for precision oncology. Through its proprietary “Trusted Data Space” (secure sandbox) privacy computing architecture, LinZight realizes the core tenet of “data usable yet invisible,” ensuring that raw patient data never leaves its institutional custody.

Furthermore, the LinZight Agentic AI framework propels artificial intelligence from “passive response” to “autonomous execution.” Integrating over 700 specialized AI agents, proprietary biomedical knowledge graphs, and biostatistical tool suites, this framework orchestrates high-throughput processing and deep analytics across comprehensive, full-dimensional real-world datasets.

The findings from this joint study were officially presented at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Presented at AACR-NCI-EORTC conference, Oct. 23, 2025; Boston, MA) and have successfully completed institutional ethical reviews and regulatory compliance filings.

bda81fca9d9349d3cdb04c544d4b9974.png

Executive Leadership Perspectives

854d6f9909491846840940c6343130e3.jpg

Dr. Lin Ni, CEO of LinZight
“This collaboration eloquently illustrates the powerful analytical capabilities of the LinZight AI computing platform. In just three months, we executed the end-to-end trajectory from deep data mining and novel mechanism discovery to biomarker validation, successfully pinpointing the precise potential beneficiary cohort for EpimAb’s innovative therapy. Such velocity and clinical depth demonstrate the transformative value of coupling high-quality real-world data with an Agentic AI platform to de-risk and expedite novel drug development in precision oncology.”

吴辰冰-1.png

Dr. Chenbing Wu, CEO of EpimAb 
“LinZight’s real-world data analytics provided a solid empirical foundation for our ALPP/G targeting strategy. The pronounced upregulation of ALPP/G in KRAS-mutant pancreatic tumors represents a vital new finding. Our EM1032 has shown outstanding in vivo anti-tumor efficacy across preclinical models; the concordance between RWD findings and our experimental preclinical data substantially bolsters our confidence as we advance EM1032 into downstream clinical development.”


About LinZight

Shanghai LinZight Technology Co., Ltd. is an innovative healthcare intelligence platform driven by “Multi-omics + Real-World Data + AI,” dedicated to unlocking the clinical value of biomedical big data. Powered by its proprietary convergence engine, LinZight provides global biopharmaceutical companies, clinical hospitals, and research institutions with world-class biomarker discovery, differentiated clinical positioning strategies, and AI-enabled drug exploration services.

To date, LinZight has forged strategic partnerships with multinational pharmaceutical corporations, pioneering biotech enterprises, and national healthcare data networks, actively contributing to industry ecosystem building. While strictly upholding patient data privacy and regulatory compliance, LinZight is committed to bridging data silos and healthcare disparities in complex disease areas, accelerating drug development pipelines, and propelling the intelligent transformation of precision oncology.
For more information, please visit: www.linzight.com

About EpimAb

EpimAb is a clinical-stage biopharmaceutical company specializing in the development of multi-specific antibodies. Leveraging extensive internal research capabilities and proprietary technological platforms—including the patented bispecific antibody platforms FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab)—EpimAb is originating and globally advancing a distinguished portfolio of transformative preclinical and clinical oncology pipelines designed to bring life-changing clinical benefits to cancer patients worldwide.
For more information, please visit: www.epimab.com

About Tee Labs

Tee Labs is an international innovation community and incubator co-founded by seasoned entrepreneurs and venture capitalists, dedicated to advancing cutting-edge medical disciplines including novel therapeutics, in vitro diagnostics, personalized medicine, and AI-driven digital health solutions.

We offer comprehensive, end-to-end incubation support spanning wet-lab infrastructure, corporate operational functions, supply chain integration, and capital empowerment, profoundly assisting entrepreneurial ventures and expediting scientific translation. Our laboratories are equipped with universal bench instrumentation and shared analytical equipment platforms, significantly curtailing early-stage site and equipment setup timelines and allowing founders to focus purely on core scientific innovation.

Presently, Tee Labs operates an incubation footprint of approximately 2,600 m², featuring 1,500 m² of specialized wet laboratories encompassing synthetic chemistry, molecular biology, mammalian cell culture, microbiology, and Biosafety Level 2 (BSL-2) certified suites. This versatile lab infrastructure accommodates diverse multidisciplinary programs, providing emerging biotechnology startups with the unique advantage of housing collaborative cross-functional teams under a unified roof.